Immunotherapy in Melanoma | Specialty

The OncLive Immunotherapy in Melanoma condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in melanoma and other skin cancers. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment.

Dr. Olszanski Discusses Advances in Stage III Melanoma

March 30th 2019

Anthony J. Olszanski, MD, RPh, vice chair, Department of Hematology/Oncology, director, Early Drug Development Phase I Program, Fox Chase Cancer Center, discusses treatment advances in stage III melanoma.

Emerging Approaches for BRAF-Mutant Metastatic Melanoma

March 28th 2019

Treatment Sequencing in BRAF+ Metastatic Melanoma

March 28th 2019

Treatment Adherence and Response With BRAF-Targeted Therapy

March 28th 2019

BRAF/MEK Frontline Therapy in Metastatic Melanoma

March 28th 2019

Maximizing BRAF/MEK Inhibition in Melanoma

March 28th 2019

Recommendations for Managing BRAF+ Metastatic Melanoma

March 28th 2019

BRAF-Targeted Therapy in Melanoma: Toxicity Management

March 28th 2019

Treating Melanoma Patients With BRAF/MEK Dual-Targeted Therapy

March 28th 2019

The COLUMBUS Trial in BRAF-Mutant Melanoma

March 28th 2019

BRAF/MEK Combinations Available in Advanced Melanoma

March 28th 2019

BRAF/MEK Dual-Targeted Therapy in Advanced Melanoma

March 28th 2019

Addressing Challenges With BRAF Inhibitors in Melanoma

March 28th 2019

BRAF as a Driver in Melanoma

March 28th 2019

Melanoma as an Oncogene-Addicted Cancer

March 28th 2019

Gene Mutations in Melanoma

March 28th 2019

Childhood Cancer Survivors at Increased Risk for Skin Cancers

March 26th 2019

Childhood cancer survivors who had lived 5 or more years from their primary malignancy are at an increased risk of developing skin cancer compared with the general population.

Dr. Olszanski on Patient Selection for Cemiplimab Treatment in CSCC

March 24th 2019

Anthony J. Olszanski, MD, RPh, discusses the treatment selection process for use of cemiplimab in patients with cutaneous squamous cell carcinoma.

SITC Guidelines Provide a Fresh Look at Evolving Strategies for Melanoma

March 14th 2019

New therapeutic approaches for treating patients with earlier-stage melanoma who face a higher risk of recurrence are among the features of recently updated consensus guidelines from the Society for Immunotherapy of Cancer.

EU Panel Backs Extended Pembrolizumab Dosing Schedule for Single-Agent Indications

March 5th 2019

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for a new extended dosing schedule for pembrolizumab for all of the PD-1 inhibitor’s monotherapy indications in the European Union.